During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally. 

The post #WAAW: 3 x Mini-Interviews appeared first on NLS.

All over the Nordics, the innovative power is gearing up to put new products, therapies and preventive measures on the market that all help tackle AMR from various angles. 

The post #WAAW: Mini-interview Phase2Phase Biopharma appeared first on NLS.

Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).

The post Xbrane enters global licensing agreement with Intas appeared first on NLS.

Modus Therapeutics has received approval from the relevant authorities in Italy for its planned Phase IIa clinical trial with sevuparin.

The post Modus Therapeutics receives approval to initiate Phase IIa trial for Chronic Kidney Disease appeared first on NLS.

In the cross-border region Medicon Valley, a new alliance is forming to highlight not just the global challenge that antimicrobial resistance (AMR) poses but the range of solutions being developed in the life science sector.

The post #WAAW: Mini-interview Colzyx appeared first on NLS.

In Sweden, recent debate and criticism regarding approved multiple myeloma treatments has shone the spotlight on IMiDs and their effects. NLS asked Fredrik Schjesvold, MD, PhD, founder and leader of Oslo Myeloma Center, Oslo University Hospital, about these drugs and the ongoing debate. 

The post Questions raised around myeloma treatments appeared first on NLS.

Alligator Bioscience and Aptevo Therapeutics report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, with more than half of evaluable patients achieved stable disease.

The post Alligator Bioscience presents new trial results appeared first on NLS.

Research from Chalmers University of Technology, Sweden, shows that resistant bacteria can regain susceptibility to antibiotics when the treatment is combined with a material equipped with antibacterial peptides.

The post #WAAW: Material that restores the efficacy of antibiotics against resistant bacteria appeared first on NLS.

BioArctic has announced that EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic’s partner Eisai’s marketing authorization application (MAA) for lecanemab as treatment of Alzheimer’s disease.

The post CHMP issues positive recommendation for approval of lecanemab in the EU appeared first on NLS.

All over the Nordics the innovative power is gearing up to put new products, therapies, and preventive measures on the market that will tackle Antimicrobial resistance (AMR) from various angles. 

The post #WAAW: Mini-interview SNIPR Biome appeared first on NLS.